S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

BIOLASE Stock Forecast, Price & News

0.00 (0.00%)
(As of 12/3/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
16.08 million shs
Average Volume
3.88 million shs
Market Capitalization
$63.30 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BIOL News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.



BIOLASE, Inc. is a medical device company, which engages in developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.


Biolase's Earnings Outlook
November 10, 2021 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Dental equipment & supplies
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$22.78 million
Book Value
$0.20 per share


Net Income
$-16.83 million
Pretax Margin




Free Float
Market Cap
$63.30 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.04 out of 5 stars

Medical Sector

574th out of 1,388 stocks

Dental Equipment & Supplies Industry

4th out of 4 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

BIOLASE (NASDAQ:BIOL) Frequently Asked Questions

Is BIOLASE a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOLASE stock.
View analyst ratings for BIOLASE
or view top-rated stocks.

How has BIOLASE's stock price been impacted by Coronavirus (COVID-19)?

BIOLASE's stock was trading at $0.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BIOL stock has decreased by 28.8% and is now trading at $0.4130.
View which stocks have been most impacted by COVID-19

When is BIOLASE's next earnings date?

BIOLASE is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for BIOLASE

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) announced its quarterly earnings results on Wednesday, November, 10th. The medical technology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. BIOLASE had a negative trailing twelve-month return on equity of 74.97% and a negative net margin of 48.22%. During the same quarter in the prior year, the business earned ($0.21) earnings per share.
View BIOLASE's earnings history

When did BIOLASE's stock split? How did BIOLASE's stock split work?

Shares of BIOLASE reverse split on the morning of Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

What guidance has BIOLASE issued on next quarter's earnings?

BIOLASE updated its fourth quarter 2021 earnings guidance on Wednesday, December, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $10.20 M-, compared to the consensus revenue estimate of $10.62 million.

What price target have analysts set for BIOL?

3 analysts have issued 1 year target prices for BIOLASE's shares. Their forecasts range from $1.15 to $3.00. On average, they expect BIOLASE's share price to reach $2.05 in the next twelve months. This suggests a possible upside of 396.4% from the stock's current price.
View analysts' price targets for BIOLASE
or view top-rated stocks among Wall Street analysts.

Who are BIOLASE's key executives?

BIOLASE's management team includes the following people:
  • John R. Beaver, President, Chief Executive Officer & Director
  • William E. Brown, Vice President-Business Development
  • Richard R. Whipp, Vice President-Operations
  • Samuel B. Low, Chief Dental Officer, VP-Dental & Clinical Affairs
  • Matthew Wilson, Vice President-Human Resources

What is Todd Norbe's approval rating as BIOLASE's CEO?

8 employees have rated BIOLASE CEO Todd Norbe on Glassdoor.com. Todd Norbe has an approval rating of 13% among BIOLASE's employees. This puts Todd Norbe in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of BIOLASE own?

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

Who are BIOLASE's major shareholders?

BIOLASE's stock is owned by many different retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.04%), Geode Capital Management LLC (0.88%), GSA Capital Partners LLP (0.83%), Essex Investment Management Co. LLC (0.53%), Marshall Wace LLP (0.50%) and Two Sigma Advisers LP (0.26%). Company insiders that own BIOLASE stock include Jack W Schuler, John R Beaver, John R Beaver and Larry N Feinberg.
View institutional ownership trends for BIOLASE

Which major investors are buying BIOLASE stock?

BIOL stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, GSA Capital Partners LLP, Essex Investment Management Co. LLC, Marshall Wace LLP, Two Sigma Advisers LP, Geode Capital Management LLC, Two Sigma Investments LP, and Citadel Advisors LLC.
View insider buying and selling activity for BIOLASE
or or view top insider-buying stocks.

How do I buy shares of BIOLASE?

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.41.

How much money does BIOLASE make?

BIOLASE has a market capitalization of $63.30 million and generates $22.78 million in revenue each year. The medical technology company earns $-16.83 million in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does BIOLASE have?

BIOLASE employs 135 workers across the globe.

What is BIOLASE's official website?

The official website for BIOLASE is www.biolase.com.

Where are BIOLASE's headquarters?

How can I contact BIOLASE?

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The medical technology company can be reached via phone at (949) 361-1200, via email at [email protected], or via fax at 949-273-6677.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.